

Supplement 1. Baseline, Perioperative, and Outcome Characteristics of the study population before PSM

Characteristic	All (n=100)	DCB group (n=49)	CB group (n=51)	P value
Age, years ($\bar{x} \pm s$)	56.4 \pm 9.0	54.0 \pm 9.6	58.6 \pm 7.8	0.011
Male, n (%)	74 (74.0)	38 (77.6)	36 (70.6)	0.428
Risk factors, n (%)				
Hypertension	80 (80.0)	39 (79.6)	41 (80.4)	0.920
Hyperlipidemia	58 (58.0)	30 (61.2)	28 (54.9)	0.522
Diabetes	45 (45.0)	21 (42.9)	24 (47.1)	0.673
Smoking history	34 (34.0)	15 (30.6)	19 (37.3)	0.483
Hyperhomocysteinemia	17 (17.0)	7 (14.3)	10 (19.6)	0.479
mRS score, M (IQR)	1 (1)	1 (2)	1 (1)	0.100
Qualifying artery, n (%)				0.725
Internal carotid artery	10 (10)	5 (10.2)	5 (9.8)	
Middle cerebral artery	42 (42)	21 (42.9)	21 (41.2)	
Vertebral artery	21 (21)	12 (24.5)	9 (17.6)	
Basilar artery	27 (27)	11 (22.4)	16 (31.4)	
Mori typing, n (%)				0.505
Mori A	54 (54)	28 (57.1)	26 (51.0)	
Mori B	34 (34)	17 (34.7)	17 (33.3)	
Mori C	12 (12)	4 (8.2)	8 (15.7)	
Periprocedural characteristics				
Pre-treatment, M (IQR)	80 (14)	80 (10)	85 (11)	0.018
Post-treatment, M (IQR)	20 (15)	20 (15)	20 (15)	0.746
Lesion length, mm ($\bar{x} \pm s$)	6.4 \pm 2.9	6.7 \pm 3.4	6.1 \pm 2.3	0.322
vascular dissection, n (%)	30 (30)	14 (28.6)	16 (31.4)	0.760
Periprocedural complications, n (%)	3 (3)	1 (2.0)	2 (3.9)	1.000
Follow-up outcomes				
Recurrent ischemic events, n (%)	5 (5)	2 (4.1)	3 (5.9)	1.000
Restenosis, n (%)	14 (14)	2 (5.3) ^a	12 (27.9) ^b	0.015
Symptomatic restenosis, n (%)	5 (5)	1 (2.0)	4 (7.8)	0.383
Stenosis at follow-u, M (IQR)	20 (20)	20 (17.5)	30 (30)	<0.001
follow-up time, M (IQR)	12 (5)	12 (6)	12 (5)	0.450

Note: ^an=38, ^bn=43